Non-small cell lung cancer and vindesine: A review

Richard J. Gralla

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Vindesine is a new, semisynthetic vinca alkaloid that has shown activity against nonsmall cell lung cancer in phase II trials conducted at several institutions. Regimens giving vindesine weekly at 3 mg/m2 i.v. x 5 weeks have been associated with the highest response rates. The vinca alkaloid can be administered in full doses when given with cisplatin, and a major response rate of 43% has been reported for the combination. The development of new drugs continues to be a major priority in the investigation and treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)565-570
Number of pages6
JournalDrugs under Experimental and Clinical Research
Volume8
Issue number5
StatePublished - 1982
Externally publishedYes

Fingerprint

Vindesine
Vinca Alkaloids
Non-Small Cell Lung Carcinoma
Cisplatin
Lung Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Non-small cell lung cancer and vindesine : A review. / Gralla, Richard J.

In: Drugs under Experimental and Clinical Research, Vol. 8, No. 5, 1982, p. 565-570.

Research output: Contribution to journalArticle

@article{dc5f7093fa9f47ccb6f335dd19e04772,
title = "Non-small cell lung cancer and vindesine: A review",
abstract = "Vindesine is a new, semisynthetic vinca alkaloid that has shown activity against nonsmall cell lung cancer in phase II trials conducted at several institutions. Regimens giving vindesine weekly at 3 mg/m2 i.v. x 5 weeks have been associated with the highest response rates. The vinca alkaloid can be administered in full doses when given with cisplatin, and a major response rate of 43{\%} has been reported for the combination. The development of new drugs continues to be a major priority in the investigation and treatment of lung cancer.",
author = "Gralla, {Richard J.}",
year = "1982",
language = "English (US)",
volume = "8",
pages = "565--570",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "5",

}

TY - JOUR

T1 - Non-small cell lung cancer and vindesine

T2 - A review

AU - Gralla, Richard J.

PY - 1982

Y1 - 1982

N2 - Vindesine is a new, semisynthetic vinca alkaloid that has shown activity against nonsmall cell lung cancer in phase II trials conducted at several institutions. Regimens giving vindesine weekly at 3 mg/m2 i.v. x 5 weeks have been associated with the highest response rates. The vinca alkaloid can be administered in full doses when given with cisplatin, and a major response rate of 43% has been reported for the combination. The development of new drugs continues to be a major priority in the investigation and treatment of lung cancer.

AB - Vindesine is a new, semisynthetic vinca alkaloid that has shown activity against nonsmall cell lung cancer in phase II trials conducted at several institutions. Regimens giving vindesine weekly at 3 mg/m2 i.v. x 5 weeks have been associated with the highest response rates. The vinca alkaloid can be administered in full doses when given with cisplatin, and a major response rate of 43% has been reported for the combination. The development of new drugs continues to be a major priority in the investigation and treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020470873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020470873&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020470873

VL - 8

SP - 565

EP - 570

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 5

ER -